Draft monograph: amycretin — disposition

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

§3.3Resulting amendments

1. The absence of a rare harm in the trial set is presented as reassurance — arising from DRAFT-AMYCRETIN-MO/001. Wherever the monograph reports that an event was not observed, it now states the total exposure and the frequency the contributing trials could have detected, so that the absence is read as the limit of the evidence rather than as a finding.
2. Storage and reconstitution guidance is given without stating what it rests on — arising from DRAFT-AMYCRETIN-MO/002. In-use periods now appear only where supported by a cited stability determination on a stated presentation, and elsewhere the monograph records that no in-use stability evidence was identified for this presentation.
3. The analytical section assumes a reference standard that is not generally available — arising from DRAFT-AMYCRETIN-MO/003. The analytical section now states whether a reference standard is in general circulation for this compound and, where it is not, states which determinations remain possible and which become qualitative. A content figure obtained without a reference standard…
4. The indication table mixes approved indications with uses for which the compound is merely supplied — arising from DRAFT-AMYCRETIN-MO/004. The indication table now carries a status column with three values, approved, under investigation and supplied without trial evidence, and the value is stated for every row. Rows in the third category also state that no certainty rating is assigned because…
5. Registered trials that never reported are absent from the monograph — arising from DRAFT-AMYCRETIN-MO/005. The trial list now includes every registered trial the Institute identified, with its reporting status stated, and the monograph reports the proportion of registered trials for which no result has been posted or published.
6. Local reactions are omitted from the adverse-event table because the trials reported them separately — arising from DRAFT-AMYCRETIN-MO/007. Local reactions are now carried in the adverse-event table wherever the source trials report them, footnoted with the convention each trial used.
7. The monograph should reproduce the approved labelling rather than paraphrase it — arising from DRAFT-AMYCRETIN-MO/008. The approved indication and contraindications are now reproduced verbatim from the named authorisation with its version and date, and the posology section reports the labelled schedule and the schedules studied side by side, with the source of each stated.
8. Anti-drug antibody data are omitted — arising from DRAFT-AMYCRETIN-MO/009. Anti-drug antibody incidence and any reported association with loss of effect are now reported where measured, and recorded as not measured where the contributing trials did not assess them.
9. What happens to weight after the compound is stopped is not in the assessed outcomes — arising from DRAFT-AMYCRETIN-MO/010. Post-withdrawal trajectory is now an assessed outcome wherever a withdrawal period was studied, rated on the same scale as the others. Where no withdrawal period was studied the outcome is recorded as not assessed.
10. Mechanistic claims for a peptide fragment are carried without evidence that the fragment acts as… — arising from DRAFT-AMYCRETIN-MO/011. Mechanistic claims not traceable to a primary source are removed, and those retained carry their source and a statement of whether the underlying work was conducted in vitro, in animals or in humans.
11. Doses are expressed in units that differ between sections — arising from DRAFT-AMYCRETIN-MO/012. A single dose unit is now used throughout each monograph, with the source unit retained in parentheses wherever a conversion was applied, and every conversion is stated rather than performed silently.
12. The document is unreadable without specialist training — arising from DRAFT-AMYCRETIN-MO/014. Every document now opens with a plain-language summary of not more than 150 words, placed above the technical abstract and carrying the same certainty language, so that the two cannot diverge.
13. The same concept is given three different names in one document — arising from DRAFT-AMYCRETIN-MO/015. A single term is now used throughout for each defined concept, and the glossary entry is linked at first use within each section rather than once per document.
14. The pharmacokinetic section does not connect half-life to the dosing schedule — arising from DRAFT-AMYCRETIN-MO/016. The pharmacokinetic section now states approximate time to steady state alongside the half-life and dosing interval, with the assumption of first-order elimination stated, and records where the assumption is not supported for this compound.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.